A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)

AIMS: To evaluate the safety and efficacy of once‐weekly dulaglutide 1.5 mg, a long‐acting glucagon‐like peptide‐1 receptor agonist, compared with placebo in patients with type 2 diabetes (T2D) on glimepiride monotherapy. METHODS: This phase III, randomized (4 : 1; dulaglutide:placebo), double‐blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Dungan, K. M., Weitgasser, R., Perez Manghi, F., Pintilei, E., Fahrbach, J. L., Jiang, H. H., Shell, J., Robertson, K. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067625/
https://www.ncbi.nlm.nih.gov/pubmed/26799540
http://dx.doi.org/10.1111/dom.12634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067625/
https://www.ncbi.nlm.nih.gov/pubmed/26799540
http://dx.doi.org/10.1111/dom.12634

Ejemplares similares